1095 related items for PubMed ID: 18071030
1. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, Mauro L, Jy W, Smith SJ.
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[Abstract] [Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
3. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M, ACT Investigators.
Neurology; 2009 Feb 10; 72(6):535-41. PubMed ID: 19204263
[Abstract] [Full Text] [Related]
4. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H, ACT Investigators.
Mult Scler; 2008 Apr 10; 14(3):370-82. PubMed ID: 18208877
[Abstract] [Full Text] [Related]
5. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V.
Mult Scler; 2010 Apr 10; 16(4):450-4. PubMed ID: 20150398
[Abstract] [Full Text] [Related]
6. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
Clin Ther; 2008 Jun 10; 30(6):1102-12. PubMed ID: 18640466
[Abstract] [Full Text] [Related]
7. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C, Ozmenoglu M, Velioglu S, Kilinc K, Orem A, Alioglu Z, Altunayoglu V.
Clin Neurol Neurosurg; 2006 Feb 10; 108(2):124-8. PubMed ID: 16412833
[Abstract] [Full Text] [Related]
8. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.
Mult Scler; 2010 May 10; 16(5):588-96. PubMed ID: 20167591
[Abstract] [Full Text] [Related]
9. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
Mult Scler; 2009 Aug 10; 15(8):965-76. PubMed ID: 19465443
[Abstract] [Full Text] [Related]
10. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
[Abstract] [Full Text] [Related]
11. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
[Abstract] [Full Text] [Related]
12. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
[Abstract] [Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ.
Clin Ther; 2006 Apr 04; 28(4):461-74. PubMed ID: 16750460
[Abstract] [Full Text] [Related]
14. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH.
Ann Neurol; 1996 Mar 04; 39(3):285-94. PubMed ID: 8602746
[Abstract] [Full Text] [Related]
15. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
[Abstract] [Full Text] [Related]
16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
Lancet Neurol; 2008 Oct 22; 7(10):903-14. PubMed ID: 18789766
[Abstract] [Full Text] [Related]
17. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X.
Mult Scler; 2008 May 22; 14(4):479-84. PubMed ID: 18562504
[Abstract] [Full Text] [Related]
18. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR, Panitch HS.
Clin Ther; 2007 Sep 22; 29(9):2031-48. PubMed ID: 18035202
[Abstract] [Full Text] [Related]
19. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT.
Neurology; 2008 Oct 28; 71(18):1390-5. PubMed ID: 18525027
[Abstract] [Full Text] [Related]
20. Rationale and design of the prospective and retrospective observational study of Avonex and Rebif (PROOF) for the treatment of relapsing-remitting multiple sclerosis.
Murray TJ.
Curr Med Res Opin; 2004 Jan 28; 20(1):25-30. PubMed ID: 14741068
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
